Immunocore Holdings plc
Immunocore Holdings plc is a commercial-stage biotechnology company built around its proprietary ImmTAX platform, which engineers TCR-based medicines to redirect the immune system against cancer, infectious diseases, and autoimmune disease. Its first approved product, KIMMTRAK, is marketed for unresectable or metastatic uveal melanoma, while the rest of the pipeline remains in clinical and preclinical development.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueApproved therapy sold to treat unresectable or metastatic uveal melanoma.
Investigational TCR-based cancer programs aimed at expanding beyond KIMMTRAK.
Clinical programs targeting chronic viral disease, including hepatitis B.
Preclinical programs designed to extend the platform into autoimmune disease.
Customers
Immunocore sells primarily to distributors, hospitals, and healthcare providers that administer KIMMTRAK to eligible patients with uveal melanoma. The end demand is driven by oncologists and treatment centers in major markets such as the United States and Europe, where reimbursement and launch execution determine uptake. For its pipeline programs, the company’s future customers would be patients, payers, and healthcare systems if and when additional products are approved.
Hospitals and specialty clinics in the United States that buy KIMMTRAK for eligible mUM patients and drive the largest revenue base.
Regional distributors and healthcare providers in Europe that purchase and dispense KIMMTRAK under local reimbursement systems.
Partners such as Medison and Er-Kim that commercialize KIMMTRAK in selected territories outside core markets.
Research centers enrolling patients in PRISM-MEL-301 and HBV studies to advance the pipeline toward approval.
Strategy
Immunocore is focused on expanding KIMMTRAK adoption in existing markets while adding new country launches through partners and direct commercialization. At the same time, it is advancing a broader pipeline in oncology, HBV, and autoimmune disease to reduce dependence on a single product and create a longer-term growth base.
KIMMTRAK is the only revenue-generating asset and funds the broader platform.
New oncology approvals would broaden the addressable market beyond uveal melanoma.
Diversification reduces single-product dependence and improves long-term optionality.
Geography
The company is headquartered in the United Kingdom, with principal offices in Abingdon and U.S. offices in Pennsylvania and Maryland. Commercial revenue is concentrated in the United States and Europe, while manufacturing and logistics are outsourced across Denmark, Germany, and the Netherlands. This geography matters because the business depends on cross-border clinical development, regulatory approvals, reimbursement negotiations, and third-party supply chains.
Risks
The company remains highly dependent on KIMMTRAK, so any slowdown in uptake, reimbursement, or supply would have an outsized effect on results. It also faces the usual biotechnology risks: clinical trial failure, regulatory delays, pricing pressure, and the need for additional capital before the pipeline can generate meaningful revenue. Because manufacturing and clinical operations are international and outsourced, supply-chain, compliance, and geopolitical risks are material.
- Single-product revenue concentrationImpact: HighLikelihood: Medium
KIMMTRAK is the only marketed product and funds most of the business.
Exposure: Commercial revenue and cash generation
- Clinical development failureImpact: HighLikelihood: Medium
Pipeline assets may not show sufficient efficacy or safety to reach approval.
Exposure - Manufacturing and supply disruptionImpact: HighLikelihood: Low
Production is outsourced to third-party CMOs and depends on compliant scale-up.
Exposure - Capital needs and dilutionImpact: HighLikelihood: Low
The company may need external funding before pipeline assets become commercial.
Exposure: R&D and commercialization funding
- International regulatory and geopolitical exposureImpact: MediumLikelihood: Medium
Operations, suppliers, and trials span multiple jurisdictions with changing rules.
Exposure
Accounting
Judgemental itemsNet revenue depends on estimates for rebates, chargebacks, and returns.
Impact: A 20% change in estimated rebate/chargeback rates moved quarterly revenue by about $1.7 million.
Revenue is recognized when control transfers, not when product is shipped in all cases.
Impact: Can shift revenue between quarters depending on distributor inventory movements.
Negotiated prices in countries such as France and Germany affect accrued deductions.
Impact: Can create one-time changes in reported revenue and margins.
The company has significant accumulated losses and limited near-term taxable profits.
Impact: Deferred tax assets may remain partially or fully reserved.
Similar listed companies
Publicly listed companies with a comparable business focus.
Immatics N.V.
IMTX · Biological Products, (No Diagnostic Substances)
IMMUTEP Ltd
IMMP · Pharmaceutical Preparations
Immutep Ltd is a clinical-stage biotechnology company developing immunotherapies for cancer and autoimmune diseases.
Imunon, Inc.
IMNN · Pharmaceutical Preparations
Iovance Biotherapeutics, Inc
IOVA · Biological Products, (No Diagnostic Substances)
Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers.
Immunome Inc.
IMNM · Pharmaceutical Preparations
Immunovant, Inc.
IMVT · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026